PMID: 9186606Apr 15, 1997Paper

Prevention of restenosis by gene therapy

Annals of the New York Academy of Sciences
Y KanedaV J Dzau

Abstract

We have developed an efficient vector system based on the liposome for the delivery of oligonucleotides and genes into various organs. The liposome was decorated with fusion proteins of HVJ (Sendai virus) to introduce DNA directly into the cytoplasm and contained DNA and DNA-binding nuclear protein inside the particle to enhance its expression. Using the vector, called HVJ-liposome gene delivery system, we attempted to prevent the neointima formation of vascular walls after balloon injury. Antisense oligonucleotides against PCNA and cdc2 kinase transferred into injured arterial walls by protein-liposomes greatly reduced the message of those genes and inhibited neointima formation of the injured artery for 8 weeks. Moreover, double-stranded oligonucleotides containing the consensus sequence for E2F binding sites inhibited the growth of smooth muscle cells and prevented neointima formation. Finally, c-NOS gene was introduced into injured rat carotid artery by HVJ-liposome, and neointima formation was inhibited by 70% for 2-4 weeks.

References

Jan 1, 1991·Cold Spring Harbor Symposia on Quantitative Biology·M MeyersonL H Tsai
Nov 1, 1990·The Journal of Clinical Investigation·H ItohV J Dzau
Feb 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·H E von der LeyenV J Dzau
Jun 1, 1995·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Y KanedaN Tomita
Jun 20, 1995·Proceedings of the National Academy of Sciences of the United States of America·R MorishitaV J Dzau
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·R MorishitaV J Dzau

❮ Previous
Next ❯

Citations

Aug 15, 1998·Trends in Pharmacological Sciences·A F ChenZ S Katusic
Aug 6, 2000·European Journal of Radiology·P WunderbaldingerR Weissleder
Nov 20, 1998·Current Opinion in Biotechnology·D SchermanJ Crouzet
Oct 23, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Toyokazu TsuchiharaHiroshi Arino
Jul 28, 2001·Clinical and Experimental Pharmacology & Physiology·D J FernandesA G Stewart
Jan 31, 2002·Plastic and Reconstructive Surgery·Oren M Tepper, Babak J Mehrara
Jan 25, 2002·Annals of the New York Academy of Sciences·B L MetcalfeM K Raizada
Oct 16, 2004·Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists·Zhonghua Sun
May 31, 2008·Expert Review of Cardiovascular Therapy·Shalini BhardwajSeppo Ylä-Herttuala
Dec 16, 2006·Endothelium : Journal of Endothelial Cell Research·Annemarie M NoordeloosP W J C Serruys
Jul 2, 2005·Expert Opinion on Emerging Drugs·J Linde, B H Strauss
Oct 25, 2011·Expert Opinion on Therapeutic Patents·Roberto Gambari

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.